Table 3. Logistic regression models predicting androgen receptor expression by IHC stains.
|
Androgen receptor staining ⩾1%
|
Androgen receptor staining >10%
|
|||
|---|---|---|---|---|
| Crude odds ratio (95% CI) | Adjusted odds ratioa (95% CI) | Crude odds ratio (95% CI) | Adjusted odds ratioa (95% CI) | |
|
BRCA1 mutation status
| ||||
| Carrier versus noncarrier | 0.33 (0.14–0.79) | 0.47 (0.17–1.3) | 0.21 (0.06–0.75) | 0.43 (0.11–1.7) |
| 5-year change in age at diagnosis | 1.2 (1.04–1.5) | 1.2 (0.97–1.4) | 1.4 (1.1–1.7) | 1.3 (1.03–1.7) |
|
Histology
| ||||
| Ductal versus mixed | 1.2 (0.26–5.8) | 0.65 (0.13–3.2) | ||
|
Tumor grade
| ||||
| 1/2 vs. 3 | 6.5 (2.0–20.9) | 3.8 (0.98–14.6) | 6.3 (1.9–21.6) | 4.6 (1.1–19.7) |
|
Lymphovascular invasion
| ||||
| Present versus absent | 1.1 (0.52–2.4) | 0.84 (0.33–2.2) | ||
|
Lymphocytic infiltrate
| ||||
| Positive/focally positive versus negative | 0.70 (0.29–1.7) | 0.53 (0.19–1.5) | ||
|
EGFR
| ||||
| Positive versus negative | 0.77 (0.34–1.8) | 1.2 (0.41–3.4) | ||
|
Cytokeratin 5/6
| ||||
| Positive versus negative | 0.77 (0.36–1.6) | 0.69 (0.28–1.7) | ||
|
Cytokeratin 14
| ||||
| Positive versus negative | 0.52 (0.24–1.1) | 0.48 (0.19–1.2) | ||
|
PD-L1 cancer
| ||||
| Positive versus negative | 2.7 (1.3–5.9) | 2.6 (1.1–6.1) | 2.3 (0.92–6.0) | 2.8 (0.98–7.8) |
|
PD-L1 cancer/inflammatory
| ||||
| Positive versus negative | 1.4 (0.30–6.7) | 1.8 (0.23–14.9) | ||
Abbreviations: CI, confidence interval; IHC, immunohistochemical.
a
Adjusted for all other variables that were significantly associated with androgen receptor staining.